CURIS INC
CRIS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRIS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRIS
Curis Inc. is a biotechnology company focused on developing emavusertib, an IRAK4 inhibitor, for hematologic cancers, currently facing significant financial challenges with a going concern warning and limited cash runway.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.6M
Cash Runway
1.9 moLead Asset
CA-170 (Phase 2/Phase 3)
Next Catalyst
Patent_Expiry · Dec 15, 2028Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials · 1 catalyst for CURIS INC.
Curis Inc. is a biotechnology company focused on developing emavusertib, an IRAK4 inhibitor, for hematologic cancers, currently facing significant financial challenges with a going concern warning and limited cash runway.
- Curis is primarily focused on its Phase 2 combination study of emavusertib in chronic lymphocytic leukemia (with zanubrutinib) and ongoing Phase 1/2 studies in relapsed/refractory primary central nervous system lymphoma (with ibrutinib) [sec · filed 2026-01-08].
- As of June 30, 2026, the company reported cash & equivalents of $5.6M, total revenue of $0.0M, net income of -$8.6M, and shareholders' equity of -$14.0M [sec].
- The company completed an August 2026 public offering for estimated net proceeds of approximately $4.8 million, extending its cash runway into the fourth quarter of 2026 [sec_mda · as of 2026-08-14].
- Curis has a substantial doubt about its ability to continue as a going concern, stating it does not have sufficient cash on hand to support operations beyond the next 12 months [sec · filed 2026-08-10].
What works
- Curis has an ongoing clinical program for emavusertib in two indications (CLL and PCNSL), with combination studies already initiated [sec · filed 2026-01-08].
- The company successfully raised additional capital through a PIPE financing in January 2026 and a public offering in August 2026, demonstrating some access to capital markets [sec · filed 2026-01-08][sec_mda · as of 2026-08-14].
What to weigh
- Curis has no approved products and has generated zero revenue, with a net loss of $8.6M in the latest quarter [sec].
- The company has a going concern warning, with cash and equivalents of only $5.6M as of June 30, 2026, and expects to exhaust its capital resources in the fourth quarter of 2026 [sec · filed 2026-08-10][sec_mda · as of 2026-08-14].
- Curis faces substantial uncertainty in completing clinical development and obtaining regulatory approval for emavusertib, with risks of adverse results, delays, or failure [sec · filed 2025-03-28].
- The company has negative shareholders' equity of -$14.0M, indicating accumulated deficits exceed assets [sec].
From the filings
Quoted directly from source documents.
Curis has a going concern warning and limited cash runway.
“we do not have sufficient cash on hand to support current operations beyond the next 12 months. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
SEC filings · August 10, 2026
Curis is focusing on emavusertib clinical trials.
“The Company is focusing its operations on its recently initiated Phase 2 combination study of emavusertib in chronic lymphocytic leukemia (with zanubrutinib) and its ongoing combination Phase 1/2 studies in relapsed/refractory primary central nervous system lymphoma (with ibrutinib).”
SEC filings · January 8, 2026
Curis completed an August 2026 public offering.
“In August 2026, we completed the August 2026 Public Offering for estimated net proceeds of approximately $4.8 million”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2028-12-15 · Patent_Expiry · ERIVEDGE — Patent/Exclusivity Expiry: ERIVEDGE — The patent/exclusivity for ERIVEDGE is set to expire, which could impact any associated royalty or revenue streams.
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as going concern; cash expected to fund operations only into Q4 2026 [sec · filed 2026-08-10].
- Clinical development failure — Emavusertib may fail to show sufficient safety/efficacy or may not achieve regulatory approval [sec · filed 2025-03-28].
- Dilutive financing need — Company requires substantial additional capital immediately; future financing may be dilutive or unavailable [sec_mda · as of 2026-08-14].
- No revenue or profitability — No approved products, zero revenue, and expects to not achieve profitability in foreseeable future [sec].
What to watch
- Cash runway and ability to raise additional capital before Q4 2026 [sec_mda · as of 2026-08-14].
- Enrollment and data from the Phase 2 combination study of emavusertib in CLL and Phase 1/2 study in PCNSL [sec · filed 2026-01-08].
- Any regulatory filings or updates on emavusertib's path to approval [sec · filed 2025-03-28].
- Potential patent expiry of ERIVEDGE on 2028-12-15, which may affect related revenue streams [catalyst].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run CURIS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CURIS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
1.9 months
D/E 3.04 · 0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~838d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| sphera funds management ltd. | 1,994,937 | $1.1M |
| vanguard capital management llc | 748,652 | $410K |
| renaissance technologies llc | 366,740 | $201K |
| morgan stanley | 254,245 | $139K |
| geode capital management, llc | 168,327 | $92K |
| cm management, llc | 150,000 | $82K |
| focused wealth management, inc | 109,746 | $60K |
| citadel advisors llc | 67,018 | $37K |
| boothbay fund management, llc | 62,168 | $34K |
| vanguard fiduciary trust co | 61,664 | $34K |
Showing top 10 of 36 institutional holders of CURIS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 0.3
- Shares short
- 262,332
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRIS short interestGovernance
Frequently asked questions
What is the AI investment thesis for CURIS INC?
Curis Inc. is a biotechnology company focused on developing emavusertib, an IRAK4 inhibitor, for hematologic cancers, currently facing significant financial challenges with a going concern warning and limited cash runway.
What is CURIS INC's lead drug candidate?
CURIS INC's most advanced tracked candidate is CA-170 (Phase 2/Phase 3) for Being evaluated in combination with chemoradiation in non-squamous non-small cell lung cancer (Phase 2b/3 randomized study).
What is CURIS INC's next catalyst?
CURIS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ERIVEDGE" — expected December 15, 2028.
Who is the CEO of CURIS INC?
Mr. James E. Dentzer is the chief executive officer of CURIS INC (CRIS).
Where is CURIS INC headquartered?
CURIS INC (CRIS) is headquartered in Lexington, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.